A real-world, preprint study in medRxiv found that people with overweight or obesity were up to with tirzepatide (Mounjaro) than with semaglutide (Ozempic), though the study used formulations for type 2 diabetes, in which semaglutide comes at a lower dose than its formulation for chronic weight management (Wegovy).
Speaking of which, why did Eli Lilly give for its obesity indication? (Endpoints News)
These appetite-curbing obesity meds may have people differently. (NPR)
The used to remove soft tissues like thyroid nodules, said Baird Medical.
The in the first half of 2023 in states with abortion bans compared with states that did not have bans, a study found. (CNN)
In patients receiving testosterone for gender-affirming hormone therapy (GAHT), were associated with significantly higher hematocrit levels, but absolute levels remained in the normal range and erythrocytosis was rare. (Journal of Clinical Endocrinology & Metabolism)
A meta-analysis found ones significantly lowered the risk of type 2 diabetes incidence, cardiovascular disease, and all-cause mortality. (BMC Medicine)
A for people deficient in the hormone leptin was both safe and effective in a phase I study. (Science Translational Medicine)
Disease-modifying anti-rheumatic drugs used for rheumatoid arthritis may help prevent the , too. (Journal of Internal Medicine)
Growth hormone (GH) secretion was inversely tied with in those with GH deficiency caused by nonfunctioning pituitary masses. (Journal of the Endocrine Society)
improved health outcomes for people with diabetes and those on Medicaid. (STAT)
Semaglutide-maker Novo Nordisk will invest $2.3 billion into in France in order to keep up with growing demand. (Reuters)
![author['full_name']](https://clf1.medpagetoday.com/media/images/author/kristenMonaco_188.jpg)